Mizuho lifts target for ResMed stock to USD 240.00

Published on 10/15/2026 at 22:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed will report first-quarter fiscal 2027 results on October 29, 2026. ResMed stock costs EUR 216.05 on October 15, 2026 at 10:42 p.m. CEST.

Analyst target and earnings date

Mizuho raised its ResMed target from USD 235.00 to USD 240.00 on October 13, 2026.
ResMed plans to report first-quarter fiscal 2027 results on October 29, 2026.
ResMed stock costs EUR 216.05 at Lang & Schwarz on October 15, 2026 at 10:42 p.m. CEST, while NYSE trading was plus 2.95 percent.
ResMed carried a P/E ratio of 23.29 and a market capitalization of USD 34.1 billion on October 15, 2026.

Unbranded CPAP-Gerät mit Atemmaske und Schlauch auf einem Nachttisch im Schlafzimmer — ResMed Inc. (ISIN US7611521078): generisches CPAP-Atemgerät mit Maske und Schlauch steht auf einem Nachttisch, Illustration mit AI erstellt.

ResMed Inc. (ISIN US7611521078) is heading toward an analyst test after Mizuho lifted its target from USD 235.00 to USD 240.00 on October 13, 2026, leaving the target 0.92 percent below the NYSE price of USD 242.23. Markets Insider reported that analyst Anthony Petrone retained an Outperform rating. ResMed plans to release first-quarter fiscal 2027 results on October 29, 2026, after the New York Stock Exchange closes. At Lang & Schwarz, the stock was trading at EUR 216.05 on October 15, 2026 at 10:42 p.m. CEST.

Analyst target trails home price

The Mizuho target is USD 2.23 below the NYSE price of USD 242.23, a gap of 0.92 percent. The target revision came as part of a medical-device earnings preview, while the analyst kept the Outperform rating on ResMed stock.

Range leaves room above USD 242.23

ResMed traded at USD 242.23 on the NYSE at 4:00 p.m. ET on October 15, 2026, up 2.95 percent from USD 235.29. The stock stood 34.37 percent above its 52-week low of USD 180.27 and 12.77 percent below its 52-week high of USD 277.67. Volume reached 1,072,806 shares against an average of 1,288,035.

Valuation and October 29 results

ResMed had a market capitalization of USD 34.1 billion, a P/E ratio of 23.29 and a dividend yield of 1.00 percent on October 15, 2026. The October 29 reporting date gives investors the next scheduled company-specific checkpoint, with the release planned after the NYSE close and the webcast at 4:30 p.m. ET.

Comparison with peers

ResMed Inc. (NYSE, USD): plus 2.95 percent, P/E 23.29, market capitalization USD 34.1 billion

Koninklijke Philips N.V. (NYSE, USD): plus 1.96 percent, P/E 19.59, market capitalization USD 24.6 billion

Becton, Dickinson and Company (NYSE, USD): plus 2.58 percent, P/E 58.36, market capitalization USD 52.8 billion

Euro quote after hours

The euro quotation places ResMed at EUR 216.05 in late Berlin trading, while the NYSE session supplied the separate home-market move of plus 2.95 percent. The next major date is October 29, 2026, when ResMed is scheduled to publish its first-quarter fiscal 2027 results. The further course of trading is shown by the continuously updated real-time quote of ResMed stock.